The discovery of activating mutations in epidermal growth factor receptor (EGFR)and their use as predictive biomarkers to tailor patient therapy with EGFR TKIs has revolutionized the treatment of patients with advanced EGFR-mutant NSCLC (5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.